Quantum BioPharma Receives FDA Clearance For Lucid-MS Phase 2 Trial

Quantum BioPharma received FDA clearance to initiate a Phase 2 trial of Lucid-MS, its investigational treatment for multiple sclerosis. The authorization advances the company’s clinical development program and represents a meaningful regulatory milestone, though efficacy and commercial prospects remain dependent on trial results.